Bibliography
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001
- Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011;17:448-54
- Cystic Fibrosis Foundation patient data registry report. Available from: www.cff.org/livingwithcf/qualityimprovement/patientdataregistryreport [Accessed 16 February 2014]
- Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9
- Colombo C, Eleemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011;10(Suppl 2):S24-8
- Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012;47:523-33
- Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5:177-85
- Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-65
- Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013;45:1160-7
- ClinicalTrials.gov. A service of the National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results?term=CFTR&Search=Search [Accessed 16 February 2014]
- Konstan M, Kerem E, DeBoeck K, et al. Ataluren treatment of patients with nonsense mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014. [Epub ahead of print]
- Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-30
- Vertex drug information. Available from: http://pi.vrtx.com/files/uspi_ivacaftor.pdf [Accessed 9 February 2014]
- Accurso FJ, Rowe SM, Clancy J, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003
- Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72
- Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 Years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219-25
- Barry PJ, Plant BJ, Nair A, et al. Effects of ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease. Chest. 2014. Available from: http://journal.publications.chestnet.org/on February 2014]
- Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142:718-24
- Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18
- Boyle MP, Bell SC, Konstan MW, et al. Randomised trial of combined CFTR corrector and potentiator therapy in F508del-CFTR cystic fibrosis. Lancet Respir Med2014; doi:10.1016/S2213-2600(14)70132-8.21
- EMA Ivacaftor assessment report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002494/WC500130766.pdf [Accessed 30 May 2014]
- Australian Government. Public summary document on Ivacaftor. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/ivacaftor [Accessed 30 May 2014]
- Australian Department of Health. Access to Kalydeco through the Pharmaceutical Benefits Scheme. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/MC14-000305-pharmaceutical-benefits-scheme-listing-of-kalydeco [Accessed 30 May 2014]
- Bush A, Simmonds NJ. Hot of the breath: I’ve got a cost for-the 64 million dollar question. Thorax 2012;67:382-4
- O’Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 2013;310:1243-344
- Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ 2014;348:g1445
- Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013;143:14-18